The four changes driving medical device tariffs in 2026 are the Section 301 duties on Chinese medical goods, the new Section 301 forced labor tariff of 10% to 12.5%, the Section 232 duties already covering metals and patented pharmaceuticals, and the unfinished Section 232 investigation into medical devices themselves.
Together, these four actions replaced the tariff system that the Supreme Court struck down in February 2026.
They now sit on top of markets that iData Research sizes in the billions, including a global vascular access device market valued at $13 billion in 2025.
This guide explains each change in plain language, who it touches, and what is still undecided.
Find growth niches in minutes, not months.
Explore quick, actionable insights from the select markets.
Table of Contents
➜ What are the medical device tariffs in 2026
➜ Why Section 301 duties hit syringes, needles, and gloves hardest
➜ How the July 2026 forced labor tariff changed the baseline
➜ Why the Section 232 device investigation is still the open question
➜ How medical device tariffs show up in company results
➜ Which medical device markets are most exposed
Key Takeaways
- The Supreme Court ruled on February 20, 202,6 that the IEEPA tariffs were unlawful, which forced the current system into being.
- A Section 301 forced labor tariff of 10% or 12.5% took effect on July 24, 2026 across 60 economies.
- Chinese medical gloves and syringes carry Section 301 duties of 100%, the steepest rates in the medical supply chain.
- The Section 232 investigation into medical devices opened on September 2, 20,25 and has not produced tariffs.
- Medtronic reported that tariffs cost it 50 basis points of operating margin in fiscal 2026.
What are the medical device tariffs in 2026
There is no single medical device tariff.
Instead, the duties in force in 2026 come from four separate legal authorities that stack on each other.
The first is Section 301 of the Trade Act of 1974 as applied to China, which carries the highest rates on specific medical products.
The second is a newer Section 301 action tied to forced labor enforcement, which now sets the general baseline for most imports.
The third is Section 232 of the Trade Expansion Act of 1962, which already covers steel, aluminum, cop, and patented pharmaceuticals.
The fourth is a Section 232 investigation aimed squarely at medical equipment, which is still open.
Understanding which authority applies to a given product matters more than knowing any single headline rate.
Why Section 301 duties hit syringes, needles and gloves hardest
The sharpest rates apply to a short list of Chinese-made medical supplies.
Under the four-year review of the China Section 301 action that the U.S. Trade Representative finalized in September 2024, syringes and needles moved to a 100% additional duty on September 27, 2024.
Medical and surgical gloves rose to 50% on January 1, 2025, and then to 100% on January 1, 2026.
Disposable face masks and respirators moved to 50% on January 1, 2026.
These are among the highest tariff rates applied to any product category in the United States.
They target commodity supplies rather than complex capital equipment, which is why hospitals and group purchasing organizations feel them before device manufacturers do.
Many of these items are also not reimbursed separately, so providers absorb the cost rather than passing it through.
How the July 2026 forced labor tariff changed the baseline
The general tariff baseline changed twice in 2026.
On February 20, 2026, the Supreme Court held in Learning Resources, Inc. v. Trump that the International Emergency Economic Powers Act does not authorize the president to impose tariffs.
The administration replaced those duties with a temporary 10% surcharge under Section 122 of the Trade Act of 1974, which expired by law on July 24, 2026.
On the same day, a Section 301 action replaced it.
The U.S. Trade Representative announced duties across 60 economies found to have failed to impose or enforce a prohibition on goods produced with forced labor.
The rate is 10% for economies that impose such a prohibition or have committed to one, and 12.5% for the rest.
The Federal Register notice of action applies the duty to all products of each covered economy unless an annex exempts them.
That structure matters for medtech, because the duty attaches to country of origin rather than to a product category.
Goods already covered by an enumerated Section 232 program are exempt, as are Canadian and Mexican goods entered duty-free under USMCA.
Why the Section 232 device investigation is still the open question
The largest unresolved item for the sector is a Section 232 national security investigation into medical goods.
The Secretary of Commerce initiated it on September 2, 2025, covering personal protective equipment, medical consumables, and medical equipment including devices.
The scope is broad, running from surgical masks and gloves to catheters, IV bags, hospital beds, and wheelchairs.
As of September 202,6 the Bureau of Industry and Security still lists the investigation as open with no proclamation attached to it.
That contrasts with pharmaceuticals, where the parallel investigation produced a proclamation on April 2, 20,26 imposing a 100% tariff on patented pharmaceutical imports from July 31, 2026.
So the precedent exists, but no equivalent action has landed on devices.
Industry groups including AdvaMed and the American Hospital Association have argued for exempting essential medical products rather than taxing them.
Until Commerce acts, this remains a planning risk rather than a cost.
How medical device tariffs show up in company results
The clearest evidence of what these duties actually cost comes from company filings.
Medtronic reported on June 3, 2,026 that tariffs reduced its fiscal 2026 operating margin by 50 basis points, and by 80 basis points in the fourth quarter alone.
On the same earnings call, the company guided to roughly $250 million of tariff impact for fiscal 2027.
Johnson & Johnson, Abbott, Boston Scientific and Philips all lowered their tariff estimates through 2025 and 2026 as exemptions and trade deals took shape.
Several manufacturers responded by moving production rather than absorbing duties.
Becton Dickinson committed $2.5 billion to expanding domestic manufacturing capacity, and Abbott allocated $500 million to similar work.
The pattern is consistent across the sector.
Large diversified manufacturers absorb or reroute the cost, while smaller importers and providers carry more of it directly.
For a wider view of who these companies are, see our breakdown of the biggest MedTech companies in 2026.
Which medical device markets are most exposed
Exposure tracks disposables, not devices with the highest price tags.
Vascular access is the clearest case, because the category is built on catheters, syringes, and needles that are exactly what the China Section 301 rates target.
iData Research valued the global vascular access device market at $13 billion in 2025, growing at a CAGR of 2.4% to reach nearly $15.3 billion by 2032.
Respiratory care is a second pressure point, with the global anesthesia, respiratory and sleep management device market valued at $14 billion in 2025 and growing at a CAGR of 4.7%.
Diagnostics sits in a third position, since reagents and consumables cross borders constantly.
iData Research valued the U.S. in vitro diagnostics market at $23.9 billion in 2025, growing at a CAGR of 4.2% to reach $31.8 billion.
Our review of the leading in vitro diagnostics market companies covers who holds share in that market.
One note on method applies here.
iData Research does not publish a tariff cost forecast, so the sizing above describes market value rather than tariff burden, and the two should not be conflated.
Our explanation of how medical device market size is calculated sets out the underlying approach.
Frequently asked questions
Are there tariffs on medical devices in 2026?
Yes, but not through a single device-specific tariff.
Medical devices are covered by the Section 301 forced labor duty of 10% or 12.5% based on country of origin, and by China-specific Section 301 rates on particular products.
What is the tariff on medical gloves from China?
Medical and surgical gloves from China carry a 100% Section 301 additional duty as of January 1, 2026.
Did the Supreme Court end the tariffs?
It ended one category of them.
The February 20, 2026 ruling struck down tariffs imposed under IEEPA, but Section 232 and Section 301 duties rest on separate authority and remain in force.
Will the Section 232 investigation lead to new device tariffs?
That is undecided as of September 2026.
Commerce has not published a determination, and no proclamation covering medical devices has been issued.
Who pays for the tariffs on medical devices?
The importer of record pays the duty at entry.
For high-volume consumables that are not separately reimbursed, hospitals and surgery centers tend to absorb the increase.
Turn market painpoints into opportunities
Explore how procedure trends and competitor positioning create clear openings for industry experts in the market.
